HSC00189

HSC00189 is a novel bispecific antibody-drug conjugate (ADC) designed to target both Cadherin-6 (CDH6) and Folate Receptor alpha (FRα/FOLR1). Developed for the treatment of ovarian cancer, the drug addresses the heterogeneity of target expression in tumors by utilizing a bispecific antibody backbone. It is conjugated to HSK51892, a potent topoisomerase I inhibitor (TOP1i) payload. HSC00189 is internalized upon binding to either CDH6 or FOLR1, leading to cell death. Preclinical studies demonstrate broad cytotoxic activity, superior bystander killing compared to DXd-based ADCs, and robust antitumor efficacy in patient-derived xenograft models. It has shown a favorable safety profile in non-human primates with a highest non-severely toxic dose (HNSTD) of 50 mg/kg.